| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Challenges for taking primary and stem cells into clinical neurotransplantation trials for neurodegenerative disease
|
Dunnett, Stephen B.
|
|
2014
|
61 |
C |
p. 79-89
11 p.
|
artikel
|
| 2 |
CNS drug development in Europe — Past progress and future challenges
|
Nutt, David J.
|
|
2014
|
61 |
C |
p. 6-20
15 p.
|
artikel
|
| 3 |
Commercial viability of CNS drugs: Balancing the risk/reward profile
|
Johnson, Ginger S.
|
|
2014
|
61 |
C |
p. 21-24
4 p.
|
artikel
|
| 4 |
Development of allosteric modulators of GPCRs for treatment of CNS disorders
|
Nickols, Hilary Highfield
|
|
2014
|
61 |
C |
p. 55-71
17 p.
|
artikel
|
| 5 |
Discovery of novel anxiolytic agents — The trials and tribulations of pre-clinical models of anxiety
|
Andrews, N.A.
|
|
2014
|
61 |
C |
p. 72-78
7 p.
|
artikel
|
| 6 |
Editorial Board
|
|
|
2014
|
61 |
C |
p. ii-
1 p.
|
artikel
|
| 7 |
From preclinical to clinical development: The example of a novel treatment for obesity
|
Moore, Nicholas A.
|
|
2014
|
61 |
C |
p. 47-54
8 p.
|
artikel
|
| 8 |
Managing your patent assets
|
Di Nunzio, Mary Catherine
|
|
2014
|
61 |
C |
p. 25-31
7 p.
|
artikel
|
| 9 |
Neurological drug development: A guide for a start-up biotech
|
Blackburn, Thomas P.
|
|
2014
|
61 |
C |
p. 1-5
5 p.
|
artikel
|
| 10 |
Safety and regulatory requirements and challenge for CNS drug development
|
Gad, Shayne C.
|
|
2014
|
61 |
C |
p. 39-46
8 p.
|
artikel
|
| 11 |
Translational PET imaging research
|
Hargreaves, Richard J.
|
|
2014
|
61 |
C |
p. 32-38
7 p.
|
artikel
|
Tijdschrift beschrijving